There has been no shortage of news covered across the diabetes and drug delivery markets over the course of 2024.

Like all its peers, Abbott Laboratories ABT faced the industrywide challenges of margin pressure through 2024, stemming from ...

The companies have been involved in global patent litigation, with both having accused the other of infringing certain ...

Abbott Laboratories is rated a Buy due to growth indicators, diversified portfolio, strong profit margin. Read an investment ...

DexCom and Abbott resolve patent litigation with a cross-licensing agreement, ending disputes without royalties or financial ...

The company's first year sales came to a total of US $2000 ... with diabetes, and Perclose, a leading vascular closure devices company, marking the company's entry into vascular care.

DexCom and Abbott Diabetes Care entered a settlement and patent ... product and service that you use and your relationship with us. We may use it to: Verify your identity, personalize the content ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the ... were dropped from the US Congress' end-of-year ...